KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Net Income (2016 - 2025)

Historic Net Income for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $844.6 million.

  • Regeneron Pharmaceuticals' Net Income fell 796.56% to $844.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.5 billion, marking a year-over-year increase of 209.17%. This contributed to the annual value of $4.5 billion for FY2025, which is 209.17% up from last year.
  • Regeneron Pharmaceuticals' Net Income amounted to $844.6 million in Q4 2025, which was down 796.56% from $1.5 billion recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Net Income ranged from a high of $3.1 billion in Q2 2021 and a low of $722.0 million during Q1 2024
  • Its 5-year average for Net Income is $1.3 billion, with a median of $1.1 billion in 2021.
  • In the last 5 years, Regeneron Pharmaceuticals' Net Income skyrocketed by 24535.83% in 2021 and then crashed by 7250.31% in 2022.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Net Income stood at $2.2 billion in 2021, then plummeted by 46.29% to $1.2 billion in 2022, then dropped by 3.13% to $1.2 billion in 2023, then dropped by 20.86% to $917.7 million in 2024, then dropped by 7.97% to $844.6 million in 2025.
  • Its Net Income stands at $844.6 million for Q4 2025, versus $1.5 billion for Q3 2025 and $1.4 billion for Q2 2025.